Impact of Immunomodulatory (Imid) Containing Holding Therapy (HT) Regimens on Outcomes in Relapsed/Refractory (RRMM) Patients Receiving Chimeric Antigen Receptor - T Cell (CAR-T) Therapy (IMS 2026) - Sep 11, 2026 - Abstract #PA-242; Pres time: Sep 24, 2026; " Of the 363 patients, 164 patients received ide-cel therapy and 199 patients received cilta-cel therapy. IMiD -based HT regimens did not demonstrate a statistically significant improvement in PFS for either ide -cel or cilta -cel although they did significantly improve OS in ide-cel patients. Rates of CAR-T associated toxicities were relatively similar , demonstrating that IMiD based regimens are relatively safe . However, IMiD based HT regimens do not improve CAR-T efficacy in the clinical environment despite demonstrating improvement in T-cell selection in vitro ."
CAR T-Cell Therapy • Clinical • Immunomodulating • Multiple Myeloma
|
|
Veena B. Krishnan1; Rishil Chopra2; Hira Shaikh2; Abhiraj Saxena3; Mansi R. Shah3; Jivtesh Singh4; Prerna Mewawalla4; Chandra Kakarala5; Zena Chahine5; Abdullah M. Khan6; Emily Casteen7; Benjamin Hane7; William Muehlebach7; Murtaza Shoaib7; Lauren Scott7; Al-Ola Abdallah7; Jordan Snyder7; Jianzheng Wu7; Dinesh Pal Mudaranthakam7; Ratnayake Mudiyanselage Isuru Ratnayake7; Cindy Varga8; Shebli Atrash8
|